Hydrogel and preparation method thereof, organoid and culture method thereof, and drug detection method
By using GelMA-collagen mixed solution to form hydrogels with intersecting network structures in organoid culture, the problem of insufficient mechanical properties and biocompatibility of existing hydrogels is solved, and high mechanical strength and biocompatibility are achieved , meets the growth needs and drug testing needs of different types of organs.
Patent Information
- Application Number
- CN202311275539.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2023-08-29
- Filing Date
- 2023-09-28
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2043-09-28
AI Technical Summary
The existing hydrogels have insufficient mechanical properties and poor biocompatibility in organoid culture, making it difficult to meet the growth needs and drug detection needs of different types of organs.
Hydrogels with interlaced first and second cross-linking network structures are formed by photocuring using GelMA-collagen mixed solution, including GelMA, LAP photoinitiator, type I collagen, trichloride (2,2' -Bipyridine)ruthenium(II) hexahydrate and sodium persulfate photoinitiator adjust the concentration range to improve mechanical strength and biocompatibility.
It achieves high mechanical strength and biocompatibility of hydrogels, meets the culture needs of different types of organoids, and provides the ability to monitor cell growth status, suitable for drug detection.
Smart Images

Figure CN117327300B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a hydrogel and a preparation method thereof, an organoid and a culture method thereof, and a drug detection method. Background Art
[0002] Organoids are self-organizing cellular structures grown from pluripotent stem cells (PSCs) or multipotent tissue-resident adult stem cells (ASCs). They are valuable models for studying organ development and human diseases, and provide a valuable tissue source for a variety of biomedical applications such as drug screening and toxicology studies.
[0003] The culture of organoids usually relies on the use of tumor-derived basement membrane extracts (BME). BME hydrogels are composed of a heterogeneous mixture of extracellular matrix (ECM), proteoglycans, and growth factors from mouse sarcomas. However, BME hydrogels have weak mechanical properties and are difficult to adapt to various unique tumor microenvironments. In addition, the heterogeneity of BME components limits the precise regulation of their physical and biochemical properties. The differences between heterogeneous components and batches greatly limit the clinical applications of cells grown in this matrix, such as regenerative medicine and high-content screening.
[0004] Matrigel is currently used in organoid culture and can better meet the needs of various organoid growth. However, due to the unclear composition of Matrigel and the instability between batches, its use in large-scale and standardized organoid culture and organoid drug sensitivity screening is greatly limited.
[0005] Synthetic hydrogels are used as matrix materials to support tissue regeneration, as a delivery carrier for cells or drugs, or for cell culture. Most of the synthetic hydrogels proposed so far are single-component hydrogels, such as pure collagen, pure gelatin, polyisocyanurate polypeptide (PIC) and its modified product hydrogels or polyethylene glycol (PEG) hydrogels, etc., which have problems such as low mechanical strength, insufficient cell growth sites, poor biocompatibility, and difficulty in meeting the needs of convenient monitoring of cell growth status. At present, synthetic hydrogels composed of multiple components have also been proposed, but they have problems such as relatively complex component preparation processes, poor biocompatibility, and single mechanical strength. When culturing organoids, higher requirements are placed on the mechanical properties and biocompatibility of the culture carrier, which poses a challenge to the use of synthetic hydrogels to simulate tissue-like three-dimensional structures and construct microenvironments. Summary of the invention
[0006] The present invention aims to solve at least one of the technical problems existing in the prior art, and provides a hydrogel and a preparation method thereof, an organoid and a culture method thereof, and a drug detection method.
[0007] In one aspect of the present invention, a method for preparing a hydrogel is provided, the preparation method comprising:
[0008] Obtaining a GelMA-collagen mixed solution;
[0009] The GelMA-collagen mixed solution is a neutral solution, and the GelMA-collagen mixed solution contains GelMA, LAP photoinitiator, type I collagen, tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator and sodium persulfate photoinitiator; wherein,
[0010] In the GelMA-collagen mixed solution, the concentration range of tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate is 0.0005-0.005 mol / L;
[0011] The concentration range of the sodium persulfate photoinitiator is 0.005-0.05 mol / L;
[0012] The concentration range of the LAP photoinitiator is 0.05% to 0.5%;
[0013] The concentration range of the GelMA is 0.5% to 20%;
[0014] The concentration range of the type I collagen is 0.05-1%;
[0015] The GelMA-collagen mixed solution is photocured to form a hydrogel having a first layer of cross-linked network and a second layer of cross-linked network that are interlaced and interpenetrated; wherein the first layer of cross-linked network is formed by photocuring GelMA under the action of LAP photoinitiator;
[0016] The second layer of cross-linked network is formed by photocuring type I collagen under the action of tri(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator and sodium persulfate photoinitiator.
[0017] Optionally, the light curing time ranges from 0.5 to 5 minutes.
[0018] Another aspect of the present invention provides a hydrogel, which is prepared by the preparation method described above.
[0019] Another aspect of the present invention provides a hydrogel, comprising a first layer of cross-linked network, and a second layer of cross-linked network interlaced with the first layer of cross-linked network; wherein:
[0020] The first layer of cross-linked network is formed by photocuring of GelMA under the action of LAP photoinitiator;
[0021] The second layer of cross-linked network is formed by photocuring type I collagen under the action of tri(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator and sodium persulfate photoinitiator;
[0022] In a GelMA-collagen mixed solution formed by GelMA, LAP photoinitiator, type I collagen, tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator and sodium persulfate photoinitiator, the concentration range of tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate is 0.0005-0.005 mol / L;
[0023] The concentration range of the sodium persulfate photoinitiator is 0.005-0.05 mol / L;
[0024] The concentration range of the LAP photoinitiator is 0.05% to 0.5%;
[0025] The concentration range of the GelMA is 0.5% to 20%;
[0026] The concentration of type I collagen ranges from 0.05 to 1%.
[0027] Another aspect of the present invention provides an organoid culture method, the culture method comprising:
[0028] Forming a cell cluster solution of organoids to be cultured; the cell clusters in the cell cluster solution are obtained by digestion and separation of tumor tissue or non-tumor tissue, or by digestion and separation of tumor organoids or non-tumor organoids to be passaged;
[0029] A GelMA-collagen mixed solution is obtained, wherein the GelMA-collagen mixed solution is a neutral solution, and the GelMA-collagen mixed solution comprises GelMA, LAP photoinitiator, type I collagen, tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator and sodium persulfate photoinitiator; the GelMA-collagen mixed solution is a neutral solution; the substitution degree of the GelMA in the GelMA-collagen mixed solution is 30%-95% , the concentration range of GelMA is 0.5% to 20%, the concentration range of LAP photoinitiator is 0.05% to 0.5%; the concentration range of type I collagen in the GelMA-collagen mixed solution is 0.05 to 1%, the concentration range of tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate is 0.0005-0.005 mol / L; the concentration range of sodium persulfate photoinitiator is 0.005-0.05 mol / L;
[0030] The GelMA-collagen mixed solution is mixed with the cell mass solution, and an appropriate amount of the mixed solution is added to a culture chamber or a culture well for culturing the organoid, and subjected to photocuring to form an organoid gel having a first layer of cross-linked network and a second layer of cross-linked network that are staggered and interpenetrated; wherein the first layer of cross-linked network is formed by photocuring the GelMA under the action of the LAP photoinitiator, and the second layer of cross-linked network is formed by photocuring the type I collagen under the action of the tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator and the sodium persulfate photoinitiator;
[0031] A culture medium is added to the culture chamber or culture well containing the organoid gel, and tumor organoids or non-tumor organoids are obtained through culture.
[0032] Optionally, when the organoid is any one of liver, colorectal, pancreatic, and pancreatic cancer, the GelMA concentration in the GelMA-collagen mixed solution ranges from 0.5% to 10%, and the type I collagen concentration ranges from 0.05 to 0.5%.
[0033] Optionally, when the organoid is any one of liver cancer and colorectal cancer, the concentration of GelMA in the GelMA-collagen mixed solution ranges from 10% to 20%, and the concentration of type I collagen ranges from 0.5 to 1%.
[0034] Another aspect of the present invention provides a method for culturing lung or lung cancer organoids, the method comprising:
[0035] forming a lung or lung cancer cell cluster solution; the cell clusters in the lung or lung cancer cell cluster solution are obtained by digestion and separation of lung or lung cancer tissue, or by digestion and separation of lung or lung cancer organoids to be passaged;
[0036] A GelMA-collagen mixed solution is obtained, wherein the GelMA-collagen mixed solution comprises GelMA, a LAP photoinitiator, type I collagen, a tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator and a sodium persulfate photoinitiator; the GelMA-collagen mixed solution is a neutral solution; the degree of substitution of the GelMA in the GelMA-collagen mixed solution is 30%-95%, the concentration range of the GelMA is 0.5%-20%, and the concentration range of the LAP photoinitiator is 0.05%-0.5%; the concentration range of type I collagen in the GelMA-collagen mixed solution is 0.05-1%, the concentration range of the tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate is 0.0005-0.005 mol / L; the concentration range of the sodium persulfate photoinitiator is 0.005-0.05 mol / L;
[0037] The GelMA-collagen mixed solution is mixed with a lung or lung cancer cell mass solution, and an appropriate amount of the mixed solution is added to a culture chamber or a culture well, and subjected to photocuring to form a lung or lung cancer organoid gel having a staggered interpenetrating first-layer cross-linked network and a second-layer cross-linked network; wherein the first-layer cross-linked network is formed by photocuring the GelMA under the action of the LAP photoinitiator, and the second-layer cross-linked network is formed by photocuring the type I collagen under the action of the tri(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator and the sodium persulfate photoinitiator;
[0038] Add lung or lung cancer organoid culture medium into the culture cavity or culture well containing the lung or lung cancer organoid gel, and culture to obtain lung or lung cancer organoid.
[0039] Another aspect of the present invention provides an organoid, which is cultured using the culture method described above.
[0040] Another aspect of the present invention provides a method for drug detection using the organoid described above, the drug detection method comprising:
[0041] Introducing the drug to be tested into the organoids;
[0042] Obtain the effect result of the drug to be tested on the organoid.
[0043] The present invention proposes a hydrogel and a preparation method thereof, an organoid and a culture method thereof, and a method for drug detection, wherein the preparation method comprises: obtaining a GelMA-collagen mixed solution; the GelMA-collagen mixed solution is a neutral solution, and the GelMA-collagen mixed solution comprises GelMA, LAP photoinitiator, type I collagen, tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator, and sodium persulfate photoinitiator; the GelMA-collagen mixed solution is photocured to form an interpenetrating network hydrogel. The preparation method of the present invention is simple, the raw materials are easy to obtain, the preparation cost is low, and the obtained hydrogel has clear components, high and adjustable mechanical strength, good biocompatibility, and can meet the culture requirements of different types of organoid tissues and the requirements of monitoring cell growth status. BRIEF DESCRIPTION OF THE DRAWINGS
[0044] Figure 1 is a flowchart of a method for preparing a hydrogel according to an embodiment of the present invention;
[0045] Figure 2 is a schematic structural diagram of a hydrogel according to another embodiment of the present invention;
[0046] Figure 3 is a flowchart of an organoid culture method according to another embodiment of the present invention;
[0047] Figure 4 A flowchart of a method for culturing lung or lung cancer organoids according to another embodiment of the present invention;
[0048] Figure 5 A flowchart of a method for drug detection using organoids according to another embodiment of the present invention;
[0049] Figure 6 This is a scanning electron microscope observation image of the homemade hydrogel in Example 1 of the present invention and the control group Matrigel; wherein, Figure 6 A and B are electron microscopic images of Matrigel in the control group at 1000x and 5000x, respectively; Figure 6 C and D are electron microscope images of the homemade hydrogel of Example 1 at 1000x and 5000x, respectively;
[0050] Figure 7 This is a microscopic observation picture of the homemade hydrogel in Example 2 of the present invention and the control group Matrigel used to culture pancreatic cancer organoids;
[0051] Figure 8 This is a microscopic observation picture of the homemade hydrogel in Example 3 of the present invention and the control group Matrigel used to culture colorectal cancer organoids;
[0052] Fig. 9 This is a microscopic observation picture of the homemade hydrogel in Example 4 of the present invention and the control group Matrigel used to culture mouse lung organoids;
[0053] Fig.10 This is a microscopic observation picture of the homemade hydrogel in Example 5 of the present invention and the control group Matrigel used to culture mouse liver organoids. DETAILED DESCRIPTION
[0054] In order to enable those skilled in the art to better understand the technical solution of the present invention, the present invention is further described in detail below in conjunction with the accompanying drawings and specific implementation methods. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the described embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative work are within the scope of protection of the present invention.
[0055] like Figure 1 As shown, in one aspect of the present invention, a method S100 for preparing a hydrogel for organoid culture is provided, comprising steps S110 to S120:
[0056] S110, obtaining a GelMA-collagen mixed solution, wherein the GelMA-collagen mixed solution is a neutral solution, and the GelMA-collagen mixed solution comprises GelMA, LAP photoinitiator, type I collagen, tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator, and sodium persulfate photoinitiator.
[0057] It should be noted that, in the present embodiment, the photocuring agent corresponding to the GelMA component is a LAP photoinitiator, and the photocuring agent corresponding to type I collagen is a tri(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator and a sodium persulfate photoinitiator. There is no specific limitation on the mixing order of the components, as long as the components and the corresponding photoinitiators are mixed before photocuring. In other words, the GelMA-collagen mixed solution includes a GelMA solution and a neutral collagen solution. GelMA and a LAP photoinitiator can be first mixed to form a GelMA solution, and then type I collagen, tri(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator and a sodium persulfate photoinitiator can be mixed to form a neutral collagen solution, and then the two can be mixed to form a GelMA-collagen mixed solution; or a neutral collagen solution can be formed first, and then a GelMA solution can be formed, and then the two can be mixed to form a GelMA-collagen mixed solution. Of course, in addition to the above sequence, the two solutions can also be formed simultaneously, or the formation process of one solution can be performed simultaneously with the mixing process of the two solutions. For example, type I collagen solution, tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator, and sodium persulfate photoinitiator are added to the GelMA solution to obtain a GelMA-collagen mixed solution; or, the GelMA solution and LAP photoinitiator are added to a neutral collagen solution to obtain a GelMA-collagen mixed solution.
[0058] Exemplarily, in some preferred embodiments, the process of forming a GelMA-collagen mixed solution includes the following specific steps: dissolving GelMA in water, adding phenyl-2,4,6-trimethylbenzoyl lithium phosphite (LAP) photoinitiator, mixing evenly in the dark to obtain a GelMA solution, adding type I collagen to the GelMA solution, adding tri(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator and sodium persulfate photoinitiator, mixing evenly in the dark to obtain a GelMA-collagen mixed solution.
[0059] Exemplarily, in other preferred embodiments, the process of forming a GelMA-collagen mixed solution includes the following specific steps: first dissolving type I collagen in an acetic acid solution, then adding NaOH to adjust the pH to neutral, adding initiators tri(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator and sodium persulfate photoinitiator, mixing evenly in the dark, to obtain a neutral collagen solution; then adding GelMA to the neutral collagen solution, adding a certain amount of LAP photoinitiator, mixing evenly in the dark, to obtain a GelMA-collagen mixed solution.
[0060] In some preferred embodiments, type I collagen is naturally extracted animal collagen or recombinant collagen prepared by microbial method.
[0061] In the GelMA-collagen mixed solution, the GelMA substitution degree is 30% to 95%; the GelMA concentration is 0.5% to 20%; the LAP photoinitiator concentration is 0.05% to 0.5%; the type I collagen concentration is 0.05 to 1%; the tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator concentration is 0.0005 to 0.005 mol / L; the sodium persulfate photoinitiator concentration is 0.005 to 0.05 mol / L. The above concentration ranges of LAP, GelMA and type I collagen are in mass volume ratio.
[0062] In some preferred embodiments, the concentration of GelMA may preferably be 0.5% to 10%, and the concentration of type I collagen may preferably be 0.05% to 0.5%. The mechanical strength of the hydrogel formed within the above preferred concentration range matches that of organs or tissues with a lower Young's modulus, for example, liver, colorectal, pancreatic cancer, and pancreatic cancer with a Young's modulus of several kilopascals.
[0063] In other preferred embodiments, the concentration of GelMA may preferably be 10% to 20%, and the concentration of type I collagen may preferably be 0.5 to 1%. The mechanical strength of the hydrogel formed within the above preferred concentration range matches that of organs or tissues with a higher Young's modulus, for example, liver cancer and colorectal cancer with a Young's modulus of tens of kilopascals.
[0064] The S120 and GelMA-collagen mixed solution was photocured for 0.5 to 5 minutes to form an interpenetrating network hydrogel.
[0065] Specifically, in the GelMA-collagen mixed solution, the GelMA solution is photocured to form a first layer of cross-linked network, and the neutral collagen solution is photocured to form a second layer of cross-linked network, and the first layer of cross-linked network and the second layer of cross-linked network are interlaced and interpenetrated.
[0066] It should be noted that when the above-mentioned GelMA-collagen mixed solution is used for organoid culture, it is preferably filtered through a 0.22-micron filter membrane to obtain a sterile GelMA-collagen mixed solution, and then the mixed solution is mixed with the organoid cell cluster solution to be cultured subsequently, and photocrosslinked to form a hydrogel with cells.
[0067] It should be further explained that when the hydrogel of this embodiment is used for organoid culture, under the organoid culture conditions, the type I collagen in the hydrogel can be thermosensitively solidified as needed, thereby further increasing the degree of cross-linking and improving the mechanical strength of the hydrogel. There is no need to set up a separate heating step, which greatly reduces the complexity and cost of the preparation process and shortens the time of the preparation process.
[0068] The hydrogel preparation process of the present invention is simple. Based on the fact that each of the two components has its own photoinitiator, an interpenetrating network structure is formed through double cross-linking photocuring polymerization, which effectively improves the degree of cross-linking and further effectively improves the mechanical strength of the hydrogel. Secondly, based on the adjustment of the concentration of each component during the preparation process, hydrogels with different mechanical strengths are formed. Furthermore, type I collagen is photocured under the action of tri(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator and sodium persulfate photoinitiator to form a transparent hydrogel, which is convenient for observing the growth state of organoid tissue.
[0069] In another aspect of the present invention, a hydrogel for organoid culture is provided. The hydrogel is prepared by the method described above. For the specific preparation process, please refer to the above description and will not be repeated here.
[0070] like Figure 2 As shown, the hydrogel includes: a first layer of cross-linked network, and a second layer of cross-linked network interlaced with the first layer of cross-linked network; wherein the first layer of cross-linked network is formed by photocuring of GelMA under the action of LAP photoinitiator; the second layer of cross-linked network is formed by photocuring of type I collagen under the action of tri(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator and sodium persulfate photoinitiator.
[0071] In this embodiment, under light irradiation conditions, the double bonds of GelMA polymerize to form a first layer of cross-linked network, and the tyrosine residues on type I collagen undergo an oxidative coupling reaction to form a second layer of cross-linked network. The two layers of network structure are linked by the carboxyl groups on the collagen and the amino groups on the partially double-bonded GelMA to form an interpenetrating network with strong mechanical properties.
[0072] It should be noted that, in the process of preparing the hydrogel, GelMA, LAP photoinitiator, type I collagen, tri(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator and sodium persulfate photoinitiator are mixed to form a GelMA-collagen mixed solution, which is then photocured to form a two-layer interpenetrating cross-linked network. In the GelMA-collagen mixed solution, the concentration of tri(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate ranges from 0.0005-0.005 mol / L; the concentration of sodium persulfate photoinitiator ranges from 0.005-0.05 mol / L; the concentration of LAP photoinitiator ranges from 0.05% to 0.5%; the concentration of GelMA ranges from 0.5% to 20%; and the concentration of type I collagen ranges from 0.05 to 1%.
[0073] In this embodiment, the hydrogel has an interpenetrating network structure and a porous structure with dense pores and rich pore levels, which is beneficial to supplement the active sites required for specific cell growth and support the three-dimensional growth of cells; secondly, the hydrogel composition of this embodiment is clear, including only GelMA and type I collagen, and is transparent. It has the advantages of good biological activity, high mechanical strength and adjustability, and can meet the culture needs of different types of organoid tissues, overcoming the problem that the existing hydrogels using collagen are difficult to simultaneously meet the needs of high-definition observation and measurement of the growth status and drug testing status of organoid tissues, as well as the needs of organoid tissue growth activity.
[0074] like Figure 3 As shown, another aspect of the present invention provides an organoid culture method S200, comprising the following steps S210 to S230:
[0075] S210, forming a cell cluster solution for organoids to be cultured, wherein the cell clusters in the cell cluster solution are obtained by digestion and separation of primary tumor tissue or non-tumor tissue, or are obtained by digestion and separation of tumor organoids or non-tumor organoids to be passaged.
[0076] It should be noted that, in this embodiment, the organoids to be cultured may include non-tumor organoids, such as mouse pancreas, colorectal / small intestine, liver, etc., and may also be tumor organoids, such as liver cancer, colorectal cancer, etc. In other words, pancreatic cancer tissue, colorectal cancer tissue, liver cancer tissue, etc. are digested to obtain the corresponding cancer tissue, or mouse pancreas, colorectal / small intestine, liver, etc. are digested to obtain normal tissue cell mass precipitation, and then the corresponding cancer tissue or the cell mass precipitation is resuspended to obtain a cell mass solution.
[0077] Specifically, select the above-mentioned organoids for primary extraction or to be passaged, add pre-cooled PBS to the culture well plate, add 1 mL of PBS to each well, collect into a centrifuge tube, and refrigerate at 4°C for 15 min; centrifuge (1000 rpm, 5 min), remove the supernatant, and obtain an organoid precipitate; add Tryple E for enzymatic hydrolysis for 1 min; centrifuge (1000 rpm, 5 min), remove the supernatant, and obtain a precipitate; add PBS and centrifuge again (1000 rpm, 5 min) to remove excess enzyme solution to obtain a precipitate, and then resuspend the precipitate to obtain a cell mass solution.
[0078] S220. Obtain a GelMA-collagen mixed solution, which contains GelMA, LAP photoinitiator, type I collagen, tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator and sodium persulfate photoinitiator, wherein the degree of substitution of GelMA in the GelMA-collagen mixed solution is 30%-95%, the concentration range of GelMA is 0.5%-20%, and the concentration range of LAP photoinitiator is 0.05%-0.5%; the concentration range of type I collagen in the GelMA-collagen mixed solution is 0.05-1%, the concentration range of tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate is 0.0005-0.005 mol / L; the concentration range of sodium persulfate photoinitiator is 0.005-0.05 mol / L. For the specific formation process, please refer to the previous record.
[0079] S230, mixing the GelMA-collagen mixed solution with the cell mass solution, taking an appropriate amount of the mixed solution and adding it into a culture chamber or culture well for culturing organoids, and forming an organoid gel through photocuring.
[0080] Specifically, the GelMA-collagen mixed solution and the cell cluster precipitation solution are mixed in a ratio of 85:15 (v / v) to form a cell-gel mixed solution, and the cell-gel mixed solution is added to the culture well or culture chamber at a volume of 5-30 μl per well and 50-500 organoids per well. After that, it is irradiated under blue light for 0.5-5 min to cross-link into gel to form an organoid gel containing cells.
[0081] Among them, in the cross-linking gelation process, in the mixed solution of GelMA-collagen mixed solution and cell cluster solution, GelMA is photocured under the action of LAP photoinitiator to form a first layer of cross-linked network, and type I collagen is photocured under the action of tri(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator and sodium persulfate photoinitiator to form a second layer of cross-linked network. The first cross-linked network and the second cross-linked network are interlaced and interpenetrated, that is, an interpenetrating network organoid gel containing cells is formed.
[0082] S240. Add culture medium to the culture chamber or culture well containing the organoid gel, and obtain tumor organoids or non-tumor organoids through cultivation.
[0083] Specifically, the corresponding organoid culture medium is added to the above-mentioned culture wells or culture chambers, and the culture is placed in an incubator at 37° C., 5% CO 2 , and 95% humidity for culture to perform organoid expansion culture.
[0084] Furthermore, the expanded organoids are digested to obtain organoid cell clusters, which are resuspended in a GelMA-collagen mixed solution and added to a culture chamber or culture well at a rate of 10 to 50 organoids per well. They are irradiated with blue light for 0.5 to 5 minutes to form gels, and the corresponding organoid culture medium is added. The cells are placed in an incubator at 37°C, 5% CO2, and 95% humidity for culture. After 1 to 3 days, the culture medium containing the drug to be tested is replaced, and cell activity is detected after 5 to 10 days of culture.
[0085] It should be noted that when culturing organoids at the above-mentioned culture temperature, the type I collagen in the hydrogel can be further thermosensitively cross-linked as needed to improve the mechanical strength of the hydrogel.
[0086] It should be further explained that, in this embodiment, for organoids with different Young's moduli, hydrogels with different mechanical strengths can be formed by adjusting the concentration of each component during the hydrogel preparation process to match the organoids with different Young's moduli.
[0087] Exemplarily, when the organoid is an organoid with a low Young's modulus (several kilopascals), for example, liver, colorectal, pancreatic / pancreatic cancer, etc., the preparation method of the organoid gel is as follows:
[0088] S1. Dissolve GelMA in water, add initiator phenyl-2,4,6-trimethylbenzoyl lithium phosphite (LAP), and mix evenly in the dark to obtain a GelMA mixed solution; add type I collagen to the GelMA mixed solution, add initiators tri(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate and sodium persulfate, and mix evenly in the dark, and filter through a 0.22 micron filter membrane to obtain a sterile GelMA-collagen mixed solution;
[0089] In step S1, in the GelMA mixed solution, the GelMA substitution degree is 30% to 95%, the GelMA concentration is 0.5% to 10%, the concentration of the initiator LAP is 0.05% to 0.5%, in the GelMA-collagen mixed solution, the collagen concentration is 0.05 to 0.5%, the concentration of the initiator tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate is 0.0005-0.005 mol / L, and the concentration of sodium persulfate is 0.005-0.05 mol / L.
[0090] S2. Select the primary extracted or to-be-passaged organoids, add pre-cooled PBS to the culture well plate, add 1 mL of PBS to each well, collect into a centrifuge tube, and refrigerate at 4°C for 15 min; centrifuge (1000 rpm, 5 min), remove the supernatant to obtain an organoid precipitate; add Tryple E for enzymatic hydrolysis for 1 min; centrifuge (1000 rpm, 5 min), remove the supernatant to obtain a precipitate; add PBS and centrifuge again (1000 rpm, 5 min) to remove excess enzyme solution to obtain a precipitate, and resuspend to obtain a cell mass solution;
[0091] S3. Mix the sterile GelMA-collagen mixed solution and the cell cluster solution in a ratio of 85:15 (v / v), and drip the gel into the culture well plate at a rate of 5 to 30 μl per well to obtain a cell-gel mixed solution; cross-link under blue light for 0.5 to 5 minutes to obtain an organoid gel, and add the corresponding culture medium for culture and observation.
[0092] Exemplarily, when the organoid is an organoid with a high Young's modulus (tens of kilopascals), for example, liver cancer, colorectal cancer, etc., the method for preparing the organoid gel is as follows:
[0093] S1. Dissolve GelMA in water, add initiator phenyl-2,4,6-trimethylbenzoyl lithium phosphite (LAP), and mix evenly in the dark to obtain a GelMA mixed solution; add type I collagen to the GelMA mixed solution, add initiators tri(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate and sodium persulfate, and mix evenly in the dark, and filter through a 0.22 micron filter membrane to obtain a sterile GelMA-collagen mixed solution;
[0094] In step S1, in the GelMA mixed solution, the GelMA substitution degree is 30% to 95%, the GelMA concentration is 10% to 20%, the concentration of the initiator LAP is 0.05% to 0.5%, in the GelMA-collagen mixed solution, the collagen concentration is 0.5 to 1%, the concentration of the initiator tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate is 0.0005-0.005 mol / L, and the concentration of sodium persulfate is 0.005-0.05 mol / L.
[0095] S2. Select the primary extracted or to-be-passaged organoids, add pre-cooled PBS to the culture well plate, add 1 mL of PBS to each well, collect into a centrifuge tube, and refrigerate at 4°C for 15 min; centrifuge (1000 rpm, 5 min), remove the supernatant to obtain an organoid precipitate; add Tryple E for enzymatic hydrolysis for 1 min; centrifuge (1000 rpm, 5 min), remove the supernatant to obtain a precipitate; add PBS and centrifuge again (1000 rpm, 5 min) to remove excess enzyme solution to obtain a precipitate, and resuspend to obtain a cell mass solution;
[0096] S3. Mix the sterile GelMA-collagen mixed solution and the cell cluster solution in a ratio of 85:15 (v / v), and drip the gel into the culture well plate at a rate of 5 to 30 μl per well to obtain a cell-gel mixed solution; cross-link under blue light for 0.5 to 5 minutes to obtain an organoid gel, and add the corresponding culture medium for culture and observation.
[0097] In this embodiment, when the interpenetrating network hydrogel is used to culture organoids, a reliable in vitro model of organoids is formed. The culture method is simple and easy to operate. By adjusting the concentration of the components in the hydrogel, hydrogels with different mechanical strengths are formed to meet the mechanical strength and biological activity required by different organoids.
[0098] like Figure 4 As shown, another aspect of the present invention provides a method S300 for culturing lung or lung cancer organoids, comprising the following steps S310 to S340:
[0099] S310, forming a lung or lung cancer cell cluster solution; wherein the cell clusters in the lung or lung cancer cell cluster solution are obtained by digestion and separation of lung or lung cancer tissue, or by digestion and separation of lung or lung cancer organoids to be passaged;
[0100] S320, obtaining a GelMA-collagen mixed solution, which contains GelMA, LAP photoinitiator, type I collagen, tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator and sodium persulfate photoinitiator; the GelMA-collagen mixed solution is a neutral solution; wherein, the degree of substitution of GelMA in the GelMA-collagen mixed solution is 30%-95%, the concentration range of GelMA is 0.5%-20%, and the concentration range of LAP photoinitiator is 0.05%-0.5%; the concentration range of type I collagen in the GelMA-collagen mixed solution is 0.05-1%, the concentration range of tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate is 0.0005-0.005 mol / L; the concentration range of sodium persulfate photoinitiator is 0.005-0.05 mol / L.
[0101] S330, mixing the GelMA-collagen mixed solution with the lung or lung cancer cell cluster solution, taking an appropriate amount of the mixed solution and adding it into the culture chamber or culture well, and forming a lung or lung cancer organoid gel through photocuring.
[0102] S340. Add lung or lung cancer organoid culture medium into the culture chamber or culture well containing the lung or lung cancer organoid gel, and obtain lung or lung cancer organoids through cultivation.
[0103] It should be noted that the culture process of lung or lung cancer organoids in this embodiment is the same as the culture process of other organoids described above. Please refer to the above records and will not be repeated here.
[0104] In another aspect of the present invention, an organoid is provided. A variety of organoids can be cultured using the organoid culture method described above. For the specific culture method, please refer to the above description and will not be repeated here.
[0105] Exemplarily, organoids include non-tumor organoids and tumor organoids, wherein non-tumor organoids include pancreatic organoids, colorectal organoids, small intestinal organoids, lung organoids, and liver organoids; tumor organoids include pancreatic cancer organoids, colorectal cancer organoids, lung cancer organoids, and liver cancer organoids.
[0106] In some preferred embodiments, the organoids include pancreatic cancer organoids, colorectal cancer organoids, lung cancer organoids, lung organoids, liver organoids, etc. Of course, other organoids can also be cultured according to actual needs, which are not listed here one by one.
[0107] like Figure 5 As shown, another aspect of the present invention provides a method S400 for drug detection using organoids, comprising steps S410 to S420:
[0108] S410, introducing the drug to be tested into the organoid;
[0109] S420. Obtain the effect results of the drug to be tested on the organoid.
[0110] In this embodiment, based on the above-mentioned organoid in vitro model, the complexity of the human body's specific microenvironment, extracellular matrix, etc. can be simulated to achieve drug screening, especially effective drugs for pancreatic cancer, colorectal cancer, lung cancer and other cancers can be screened.
[0111] Exemplarily, a conventional drug sensitivity test for tumor organoids is performed on a well plate, comprising the following steps:
[0112] (1) Prepare a drug-containing culture medium of appropriate concentration,
[0113] (2) Tumor cancer organoids are placed in culture wells in a non-dynamic culture environment, such as the culture wells of a 96-well plate;
[0114] (4) Observe and record the growth status of tumor organoids, remove the culture medium in the culture wells, add 100 μL of culture medium containing drug solution to each well, and place in an incubator at 37°C and 5% CO2 for culture;
[0115] (4) Observe and record the growth status of tumor organoids on days 3-5;
[0116] (5) Use CTG detection kit to detect activity. Add 100 μL CTG detection reagent to each well, shake it for 5 minutes using a shaker, and incubate it at room temperature for 25 minutes. After incubation, use a chemiluminescence enzyme reader to detect it.
[0117] Exemplarily, conventional drug sensitivity testing of tumor organoids under dynamic culture includes the following steps:
[0118] (1) Prepare drug-containing culture medium of appropriate concentration:
[0119] (2) The cultured tumor organoids are placed in a culture chamber of a dynamic culture environment, for example, a chip with three interconnected chambers is used, and the tumor organoids are placed in the middle chamber;
[0120] (3) Observe and record the growth status of tumor organoids. Remove the culture medium from the chip and add culture medium containing drug solution. Add 50 μL of culture medium to the wells on the left and right sides of the chip and 30 μL of culture medium to the middle well;
[0121] (4) After adding the drug, the chip was placed in a rocking perfusion apparatus for flow culture at 3° / 120 min;
[0122] (5) On days 3 to 5, observe and record the growth status of tumor organoids, and add 30 μL of drug-containing culture medium to the middle well;
[0123] (6) Use the CTG detection kit to perform activity detection. Discard all the culture medium from the two wells, add 20 μL of CTG diluent (1:1 dilution of CTG reagent stock solution and culture medium), add 50 μL of CTG stock solution, pipette and mix, shake for 5 minutes using a shaker, incubate at room temperature for 25 minutes, remove all the lysate, and place it in a 96-well plate with completely opaque sides and bottom. Use a chemiluminescence microplate reader for detection.
[0124] The following will further illustrate the preparation method of the hydrogel and the culture method of the organoid in combination with several specific examples:
[0125] Example 1
[0126] This example provides a method for preparing a GelMA-collagen interpenetrating network hydrogel, comprising:
[0127] S1, dissolving GelMA with a substitution degree of 60% in water, adding initiator phenyl-2,4,6-trimethylbenzoyl lithium phosphite (LAP), and mixing evenly in the dark to obtain a mixed solution with a final concentration of 2% GelMA and a LAP concentration of 0.05%;
[0128] S2, adding type I collagen to the GelMA mixed solution, adding initiator tri(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate and sodium persulfate, and mixing evenly in the dark to obtain a GelMA-collagen mixed solution, wherein the collagen concentration is 0.2%, the concentration of ruthenium(II) complex is 0.0005 mol / L, and the concentration of sodium persulfate is 0.005 mol / L;
[0129] S3, cross-linking the above GelMA-collagen mixed solution under blue light irradiation for 1 min, thus obtaining a GelMA-collagen interpenetrating network hydrogel having a structure as shown in Figure 2 shown.
[0130] Furthermore, the hydrogel obtained in Example 1 was compared with a control group of commercial matrix gel Matrigel (the commercial matrix gel Matrigel was prepared by curing at 37°C for 30 minutes). The two hydrogels obtained in the control group and this example were freeze-dried and observed using a scanning electron microscope. The results are as follows: Figure 6 As shown, compared with the matrigel in the control group, in this embodiment, the porous structure of the hydrogel has dense pores and rich pore layers, which is conducive to supporting the three-dimensional growth of cells, and the edge structure of the pores is non-smooth fibrous, which effectively improves the viscoelasticity of the hydrogel and is more conducive to the cells overcoming mechanical limitations and changing their morphology, precipitating matrix, and cell migration during organoid culture.
[0131] Example 2
[0132] This example provides a method for preparing a hydrogel and a method for using the hydrogel to culture pancreatic cancer organoids, including:
[0133] S1. Dissolve GelMA with a substitution degree of 60% in water, add initiator phenyl-2,4,6-trimethylbenzoyl lithium phosphite (LAP), and mix evenly in the dark to obtain a mixed solution with a final concentration of 10% GelMA and a LAP concentration of 0.1%;
[0134] S2. Add type I collagen to the GelMA mixed solution, add initiator tri(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate and sodium persulfate, mix evenly in the dark, and filter through a 0.22 micron filter membrane to obtain a sterile GelMA-collagen mixed solution. The collagen concentration is 0.5%, the concentration of ruthenium(II) complex is 0.001 mol / L, and the concentration of sodium persulfate is 0.01 mol / L;
[0135] S3. Select the pancreatic cancer organoids to be passaged, add pre-cooled PBS to a 24-well plate, add 1 mL of PBS to each well, collect the cells into a centrifuge tube, refrigerate at 4°C for 15 min, centrifuge (1000 rpm, 5 min), remove the supernatant, and obtain the organoid precipitate; add Tryple E for enzymatic hydrolysis for 1 min, centrifuge (1000 rpm, 5 min), remove the supernatant, and obtain the precipitate; add PBS and centrifuge again (1000 rpm, 5 min) to remove excess enzyme solution to obtain the precipitate, and resuspend the precipitate to form a cell pellet solution.
[0136] S4. Mix the sterile GelMA-collagen mixed solution and the precipitated cell cluster solution at a ratio of 85:15 (v / v), drip into a 24-well plate, 30 μl per well, and cure under blue light for 15 minutes to form a gel.
[0137] Furthermore, the pancreatic cancer organoids obtained in Example 2 were compared with the pancreatic cancer organoids formed by commercial matrix gel Matrigel in the control group (commercial matrix gel Matrigel was uniformly mixed with the precipitated cell mass solution, and the gel was dripped into a 24-well plate, 30 μl per well, solidified at 37°C for 30 min, and pancreatic cancer culture medium was added for culture to obtain pancreatic cancer organoids). Figure 7 As shown, compared with the control group, the pancreatic cancer organoids cultured with the homemade hydrogel of this example are in better condition and show an increasing trend with time, which indicates that the hydrogel of this example meets the needs of pancreatic cancer organoid culture and has the ability to culture organoids in three-dimensional cells.
[0138] Example 3
[0139] This example provides a method for preparing a hydrogel and a method for using the hydrogel to culture colorectal cancer organoids, including:
[0140] S1. Dissolve GelMA with a substitution degree of 60% in water, add initiator phenyl-2,4,6-trimethylbenzoyl lithium phosphite (LAP), and mix evenly in the dark to obtain a mixed solution with a final concentration of 12% GelMA and a LAP concentration of 0.2%;
[0141] S2. Add type I collagen to the GelMA mixed solution, add initiator tri(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate and sodium persulfate, mix evenly in the dark, and filter through a 0.22 micron filter membrane to obtain a sterile GelMA-collagen mixed solution. The collagen concentration is 0.6%, the concentration of ruthenium(II) complex is 0.001 mol / L, and the concentration of sodium persulfate is 0.01 mol / L;
[0142] S3. Select primary extracted colorectal cancer organoids, add pre-cooled PBS to a 24-well plate, add 1 mL of PBS to each well, collect into a centrifuge tube, refrigerate at 4°C for 15 min, and then centrifuge (1000 rpm, 5 min) to remove the supernatant to obtain an organoid precipitate; add Tryple E for enzymatic hydrolysis for 1 min, and then centrifuge (1000 rpm, 5 min) to remove the supernatant to obtain a precipitate; add PBS and centrifuge again (1000 rpm, 5 min) to remove excess enzyme solution to obtain a precipitate, and then resuspend the precipitate to form a cell cluster solution.
[0143] S4. Mix the sterile GelMA-collagen mixed solution and the precipitated cell cluster solution at a ratio of 85:15 (v / v), drip into a 24-well plate, 30 μl per well, and cure under blue light for 15 minutes to form a gel.
[0144] Furthermore, the colorectal cancer organoids obtained in Example 3 were compared with the colorectal cancer organoids formed by the commercial matrix gel Matrigel in the control group (the commercial matrix gel Matrigel was evenly mixed with the precipitated cell mass solution, and the gel was dripped into a 24-well plate, 30 μl per well, and solidified at 37°C for 30 min to form a gel, and the colorectal cancer culture medium was added for culture to obtain colorectal cancer organoids). Figure 8 As shown, compared with the control group, the colorectal cancer organ cultured with the homemade hydrogel of this example is in better condition and shows an increasing trend with time, which indicates that the hydrogel of this example meets the needs of rectal cancer organoid culture and has good three-dimensional cell culture organoid capacity.
[0145] Example 4
[0146] This example provides a method for preparing a hydrogel and a method for using the hydrogel to culture lung cancer organoids, including:
[0147] S1. Dissolve GelMA with a substitution degree of 30% in water, add initiator phenyl-2,4,6-trimethylbenzoyl lithium phosphite (LAP), and mix evenly in the dark to obtain a mixed solution with a final concentration of 5% GelMA and a LAP concentration of 0.05%;
[0148] S2. Add type I collagen to the GelMA mixed solution, add initiator tri(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate and sodium persulfate, mix evenly in the dark, and filter through a 0.22 micron filter membrane to obtain a GelMA-collagen mixed solution. The collagen concentration is 0.5%, the concentration of ruthenium(II) complex is 0.001 mol / L, and the concentration of sodium persulfate is 0.01 mol / L;
[0149] S3. Select the lung cancer organoids to be passaged, add pre-cooled PBS to a 24-well plate, add 1 mL of PBS to each well, collect the cells into a centrifuge tube, refrigerate at 4°C for 15 min, and then centrifuge (1000 rpm, 5 min) to remove the supernatant to obtain an organoid precipitate; add Tryple E for enzymatic hydrolysis for 1 min, and then centrifuge (1000 rpm, 5 min) to remove the supernatant to obtain a precipitate; add PBS and centrifuge again (1000 rpm, 5 min) to remove excess enzyme solution to obtain a precipitate, and then resuspend the precipitate to form a cell cluster solution.
[0150] S4. Mix the sterile GelMA-collagen mixed solution and the precipitated cell mass solution at a ratio of 85:15 (v / v), drip gel into a 24-well plate, 30 μl per well, and cure under blue light for 15 min to form a gel. Add lung cancer culture medium and culture to form lung cancer organoids after passage.
[0151] Furthermore, the lung cancer organoids obtained in Example 4 were compared with lung cancer organoids formed by commercial matrix gel Matrigel in the control group (commercial matrix gel Matrigel was uniformly mixed with the precipitated cell mass solution, and the gel was dripped into a 24-well plate, 30 μl per well, solidified at 37°C for 30 min, and mouse lung culture medium was added for culture to obtain mouse lung organoids). Fig. 9 As shown, compared with the control group, the lung cancer organoids cultured with the homemade hydrogel of this example are in better condition and show an increasing trend with time, which indicates that the hydrogel of this example meets the needs of lung cancer organoid culture and has good three-dimensional cell culture organoid capabilities.
[0152] Example 5
[0153] This example provides a method for preparing a hydrogel and a method for using the hydrogel to culture mouse liver organoids, including:
[0154] S1, dissolving GelMA with a substitution degree of 30% in water, adding initiator phenyl-2,4,6-trimethylbenzoyl lithium phosphite (LAP), and mixing evenly in the dark to obtain a mixed solution with a final concentration of 2% GelMA and a LAP concentration of 0.05%;
[0155] S2. Add type I collagen to the GelMA mixed solution, add initiator tri(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate and sodium persulfate, mix evenly in the dark, and filter through a 0.22 micron filter membrane to obtain a sterile GelMA-collagen mixed solution. The collagen concentration is 0.3%, the concentration of ruthenium(II) complex is 0.0005 mol / L, and the concentration of sodium persulfate is 0.005 mol / L;
[0156] S3. Select primary extracted mouse liver organoids, add pre-cooled PBS to a 24-well plate, add 1 mL of PBS to each well, collect into a centrifuge tube, refrigerate at 4°C for 15 min, and then centrifuge (1000 rpm, 5 min) to remove the supernatant to obtain an organoid precipitate; add Tryple E for enzymatic hydrolysis for 1 min, and then centrifuge (1000 rpm, 5 min) to remove the supernatant to obtain a precipitate; add PBS and centrifuge again (1000 rpm, 5 min) to remove excess enzyme solution to obtain a precipitate, and then resuspend the precipitate to obtain a cell pellet solution.
[0157] S4. Mix the sterile GelMA-collagen mixed solution and the precipitated cell cluster solution at a ratio of 85:15 (v / v), drip into a 24-well plate, 30 μl per well, and cure under blue light for 15 minutes to form a gel.
[0158] Furthermore, the liver organoids obtained in Example 5 were compared with the liver organoids formed by commercial Matrigel in the control group (the commercial Matrigel was evenly mixed with the precipitated cell mass solution, and the gel was dripped into a 24-well plate, 30 μl per well, solidified at 37°C for 30 min, and mouse liver culture medium was added for culture to obtain mouse liver organoids). Fig.10 As shown, compared with the control group, the mouse liver organoids cultured with the homemade hydrogel in this example were in better condition and showed an increasing trend with time, indicating that the interpenetrating network hydrogel meets the needs of liver organoid culture and has the ability to culture organoids in three-dimensional cells.
[0159] The present invention provides a hydrogel and a preparation method thereof, an organoid and a culture method thereof, and a drug detection method, which have the following beneficial effects:
[0160] First, the preparation method of the present invention is simple, the raw materials are easily available, the preparation cost is low, and in the preparation process, each component corresponds to a photoinitiator, which effectively improves the photocuring cross-linking effect, forms an interpenetrating network structure, and effectively improves the mechanical strength of the hydrogel;
[0161] Second, the hydrogel of the present invention has clear components and very good biocompatibility, and the hydrogel structure has a first layer cross-linked network structure and a second layer cross-linked network structure that are interlaced and interpenetrated, and has a porous structure with dense pores and rich pore levels, which is conducive to supplementing the active sites required for specific cell growth and cell growth and proliferation; secondly, the hydrogel has a porous structure with dense pores and rich pore levels, which is more conducive to supporting the three-dimensional growth of cells, and the fibrous structure presented at the edge of the pore effectively improves the viscoelasticity of the hydrogel, which is more conducive to the cells overcoming mechanical constraints and changing their morphology, precipitating matrix, and cell migration during organoid culture;
[0162] Third, when the hydrogel of the present invention is used for organoid culture, a reliable in vitro model is formed, which can simulate the complexity of the human body's specific microenvironment, extracellular matrix, etc., and realize the screening of effective drugs for tumors.
[0163] It is to be understood that the above embodiments are merely exemplary embodiments used to illustrate the principles of the present invention, but the present invention is not limited thereto. For those of ordinary skill in the art, various modifications and improvements can be made without departing from the spirit and essence of the present invention, and these modifications and improvements are also considered to be within the scope of protection of the present invention.
Claims
1. A method for preparing a hydrogel, characterized in that: The preparation method comprises: Obtaining a GelMA-collagen mixed solution, comprising: mixing a GelMA solution with a neutral collagen solution, wherein GelMA is dissolved in water, a LAP photoinitiator is added, and the mixture is evenly mixed in the dark to obtain a GelMA solution; type I collagen, a tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator, and a sodium persulfate photoinitiator are evenly mixed in the dark to obtain a GelMA-collagen mixed solution; The GelMA-collagen mixed solution is a neutral solution, and the GelMA-collagen mixed solution contains GelMA, LAP photoinitiator, type I collagen, tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator and sodium persulfate photoinitiator; wherein, In the GelMA-collagen mixed solution, the concentration range of tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate is 0.0005-0.005 mol / L; The concentration range of the sodium persulfate photoinitiator is 0.005-0.05 mol / L; The concentration range of the LAP photoinitiator is 0.05% to 0.5%; The concentration range of the GelMA is 0.5% to 20%; The concentration range of the type I collagen is 0.05-1%; The GelMA-collagen mixed solution is photocured to form a transparent hydrogel having a first layer of cross-linked network and a second layer of cross-linked network that are interlaced and interpenetrated; wherein the first layer of cross-linked network is formed by photocuring GelMA under the action of LAP photoinitiator; The second layer of cross-linked network is formed by photocuring type I collagen under the action of tri(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator and sodium persulfate photoinitiator; wherein, When the concentration of GelMA is 0.5% to 10% and the concentration of type I collagen is 0.05% to 0.5%, the mechanical strength of the formed hydrogel matches that of organs or tissues with lower Young's modulus; When the concentration of GelMA is 10% to 20% and the concentration of type I collagen is 0.5 to 1%, the mechanical strength of the formed hydrogel matches that of organs or tissues with a higher Young's modulus.
2. The preparation method according to claim 1, characterized in that: The light curing time ranges from 0.5 to 5 minutes.
3. A hydrogel, characterized in that The hydrogel is prepared by the preparation method described in claim 1 or 2.
4. A hydrogel, characterized in that It comprises a first layer of cross-linked network and a second layer of cross-linked network interlaced with the first layer of cross-linked network, and the hydrogel is transparent; wherein, The first layer of cross-linked network is formed by photocuring of GelMA under the action of LAP photoinitiator; The second layer of cross-linked network is formed by photocuring type I collagen under the action of tri(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator and sodium persulfate photoinitiator; In a GelMA-collagen mixed solution formed by GelMA, LAP photoinitiator, type I collagen, tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator and sodium persulfate photoinitiator, the concentration range of tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate is 0.0005-0.005 mol / L; The concentration range of the sodium persulfate photoinitiator is 0.005-0.05 mol / L; The concentration range of the LAP photoinitiator is 0.05% to 0.5%; The concentration range of the GelMA is 0.5% to 20%; The concentration range of type I collagen is 0.05-1%; wherein, When the concentration of GelMA is 0.5% to 10% and the concentration of type I collagen is 0.05% to 0.5%, the mechanical strength of the hydrogel matches that of organs or tissues with a lower Young's modulus; When the concentration of GelMA is 10% to 20% and the concentration of type I collagen is 0.5 to 1%, the mechanical strength of the hydrogel matches that of an organ or tissue with a higher Young's modulus.
5. A method for culturing an organoid, characterized in that: The culture method comprises: Forming a cell cluster solution for organoids to be cultured, comprising: mixing a GelMA solution with a neutral collagen solution, wherein GelMA is dissolved in water, a LAP photoinitiator is added, and the mixture is evenly mixed in the dark to obtain a GelMA solution; type I collagen, tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator, and sodium persulfate photoinitiator are evenly mixed in the dark to obtain a GelMA-collagen mixed solution; the cell clusters in the cell cluster solution are obtained by digestion and separation of tumor tissue or non-tumor tissue, or by digestion and separation of tumor organoids or non-tumor organoids to be passaged; A GelMA-collagen mixed solution is obtained, wherein the GelMA-collagen mixed solution is a neutral solution, and the GelMA-collagen mixed solution comprises GelMA, LAP photoinitiator, type I collagen, tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator and sodium persulfate photoinitiator; the GelMA-collagen mixed solution is a neutral solution; the substitution degree of the GelMA in the GelMA-collagen mixed solution is 30%-95% , the concentration range of GelMA is 0.5% to 20%, the concentration range of LAP photoinitiator is 0.05% to 0.5%; the concentration range of type I collagen in the GelMA-collagen mixed solution is 0.05 to 1%, the concentration range of tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate is 0.0005-0.005 mol / L, and the concentration range of sodium persulfate photoinitiator is 0.005-0.05 mol / L; The GelMA-collagen mixed solution is mixed with the cell mass solution, and an appropriate amount of the mixed solution is added to a culture chamber or a culture well for culturing the organoid, and subjected to photocuring to form a transparent organoid gel having a first layer of cross-linked network and a second layer of cross-linked network that are interlaced and interpenetrated; wherein the first layer of cross-linked network is formed by photocuring the GelMA under the action of the LAP photoinitiator, and the second layer of cross-linked network is formed by photocuring the type I collagen under the action of the tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator and the sodium persulfate photoinitiator; Adding culture medium to the culture chamber or culture well containing the organoid gel, and culturing to obtain tumor organoids or non-tumor organoids; wherein, When the concentration of GelMA is 0.5% to 10% and the concentration of type I collagen is 0.05% to 0.5%, the mechanical strength of the organoid gel matches that of tumor organoids or non-tumor organoids with a lower Young's modulus; When the concentration of GelMA is 10% to 20% and the concentration of type I collagen is 0.5 to 1%, the mechanical strength of the organoid gel matches that of tumor organoids or non-tumor organoids with a higher Young's modulus.
6. The culture method according to claim 5, characterized in that: When the organoid is any one of liver, colorectal, pancreatic, and pancreatic cancer, the concentration of GelMA in the GelMA-collagen mixed solution is in the range of 0.5% to 10%, and the concentration of type I collagen is in the range of 0.05 to 0.5%.
7. The culture method according to claim 5, characterized in that When the organoid is any one of liver cancer and colorectal cancer, the concentration of GelMA in the GelMA-collagen mixed solution is in the range of 10% to 20%, and the concentration of type I collagen is in the range of 0.5 to 1%.
8. A method for culturing lung or lung cancer organoids, characterized in that: The culture method comprises: forming a lung or lung cancer cell cluster solution; the cell clusters in the lung or lung cancer cell cluster solution are obtained by digestion and separation of lung or lung cancer tissue, or by digestion and separation of lung or lung cancer organoids to be passaged; Obtaining a GelMA-collagen mixed solution comprises: mixing a GelMA solution with a neutral collagen solution, wherein GelMA is dissolved in water, a LAP photoinitiator is added, and the mixture is mixed evenly in the dark to obtain a GelMA solution; type I collagen, a tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator, and a sodium persulfate photoinitiator are mixed evenly in the dark to obtain a GelMA-collagen mixed solution, wherein the GelMA-collagen mixed solution comprises GelMA, a LAP photoinitiator, type I collagen, a tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator, and a sodium persulfate photoinitiator; The GelMA-collagen mixed solution is a neutral solution; the substitution degree of the GelMA in the GelMA-collagen mixed solution is 30%-95%, the concentration range of the GelMA is 0.5%-10%, and the concentration range of the LAP photoinitiator is 0.05%-0.5%; the concentration range of the type I collagen in the GelMA-collagen mixed solution is 0.05-0.5%, the concentration range of tris(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate is 0.0005-0.005 mol / L; the concentration range of the sodium persulfate photoinitiator is 0.005-0.05 mol / L; The GelMA-collagen mixed solution is mixed with a lung or lung cancer cell mass solution, and an appropriate amount of the mixed solution is added to a culture chamber or a culture well, and subjected to photocuring to form a transparent lung or lung cancer organoid gel having a first layer of cross-linked network and a second layer of cross-linked network that are interlaced and interpenetrated; wherein the first layer of cross-linked network is formed by photocuring the GelMA under the action of the LAP photoinitiator, and the second layer of cross-linked network is formed by photocuring the type I collagen under the action of the tri(2,2'-bipyridyl)ruthenium(II) chloride hexahydrate photoinitiator and the sodium persulfate photoinitiator; Add lung or lung cancer organoid culture medium into the culture cavity or culture well containing the lung or lung cancer organoid gel, and culture to obtain lung or lung cancer organoid.
9. An organoid, characterized in that: The organoid is cultured using the culture method described in any one of claims 5-8.
10. A method for drug detection using the organoid as claimed in claim 9, characterized in that: The method for drug detection comprises: Introducing the drug to be tested into the organoids; Obtain the effect result of the drug to be tested on the organoid.
Citation Information
Patent Citations
Light-activated preparation of hydrogels
CN108367100A
Bio-based water-soluble negative photoresist and application thereof in femtosecond laser direct writing processing method
CN112835268A
Preparation method and application method of double-network hydrogel for three-dimensional cell culture
CN113444264A
Preparation method of photo-induced silk fibroin / gelatin co-crosslinked hydrogel suitable for 3D printing
CN113651974A
Preparation method of photocuring casein hydrogel and application of photocuring casein hydrogel in hemostasis and skin repair
CN114507364A
